Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis.

ABSTRACT:

Background & aims

Obeticholic acid (OCA), a farnesoid X receptor agonist, increases total and low-density lipoprotein cholesterol (LDL-C) in patients with non-alcoholic steatohepatitis. In the present study, we aimed to evaluate the impact of OCA therapy on lipoprotein sub-particles.

Method

This study included 196 patients (99 OCA group and 97 placebo group) who were enrolled in the FLINT trial and had samples available for lipid analysis and liver biopsies at enrollment and end-of-treatment (EOT) at 72 weeks. Very low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) particles were evaluated at baseline, 12 and 72 weeks after randomization, and 24 weeks following EOT.

Results

Baseline lipoprotein profiles were similar among

SUBMITTER: Siddiqui MS 

PROVIDER: S-EPMC6920569 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature